Ciclosporin vs a glucocorticoid (prednisolone / methylprednisolone) in dogs with atopic dermatitis — LIKELY

In dogs with atopic dermatitis, does ciclosporin vs a glucocorticoid (prednisolone or methylprednisolone) give equivalent lesion and itch control over 6–8 weeks?

Shelf #274 · gate-verified and displayed under the developer's blinded-trial rule

LIKELY: Two blinded randomised trials, one small and one large, find ciclosporin and a glucocorticoid control the lesions and itch of canine atopic dermatitis to a statistically indistinguishable degree. At exactly the 6-week point asked here, Olivry 2002 (30 dogs with nonseasonal atopic dermatitis; ciclosporin 5 mg/kg vs prednisolone 0.5 mg/kg daily) found CADESI lesion scores and owner pruritus scores fell significantly in both groups, with percentage reductions not statistically different between groups (P > 0.3). Over a longer, tapered course, Steffan 2003 (117 ciclosporin vs 59 methylprednisolone dogs, multicentre) found lesion-score reductions of 52% vs 45% and pruritus reductions of 36% vs 33% — again not significantly different — with a better overall efficacy assessment for ciclosporin (76% vs 63% rated excellent or good). After treatment stopped, ciclosporin dogs relapsed later and less often than methylprednisolone dogs (Steffan 2004). Neither trial was designed as a formal non-inferiority study with a pre-set equivalence margin, so 'equivalent' here means 'no difference detected, consistently, in blinded randomised comparisons' — strong enough for LIKELY, not proof of exact equality. Drafted Nov 10, 2026 (VetMed build, topic #274); all figures from abstracts fetched and verified at drafting.

Olivry 2002: ciclosporin vs prednisolone for 6 weeks — lesion and itch reductions not statistically different between groups (P > 0.3)

Blinded randomized controlled trial (record's own abstract wording; indexed Randomized Controlled Trial, with MeSH Double-Blind Method)

Who: Dogs: 30 dogs with nonseasonal atopic dermatitis at university/referral clinics (record MeSH indexes California, North Carolina and Virginia sites) — randomly allocated to oral NEORAL ciclosporin (5 mg/kg) or prednisolone (0.5 mg/kg) once daily for 6 weeks; clinicians graded skin lesions with the Canine AD Extent and Severity Index (CADESI) and owners assessed pruritus on a visual analog scale (PVAS) before and at 3 and 6 weeks.

Result: In both groups, CADESI and PVAS values were significantly lower at 6 weeks post treatment than before the initiation of therapy (Friedman test, P < 0.0004). The percentage reductions in CADESI and PVAS values from baseline were not statistically different between groups (Mann-Whitney test, P > 0.3). Tolerability and safety appeared similar: one-fifth of dogs given oral ciclosporin occasionally developed diarrhoea or soft stools, and one ciclosporin dog developed a generalized papillomatous skin eruption during the second half of the trial. The record concludes ciclosporin's anti-allergic efficacy appears comparable with that of prednisolone.

Watch out: Only 30 dogs and no pre-specified equivalence/non-inferiority margin: 'not statistically different' in a trial this size cannot exclude a clinically meaningful difference, which is why this shelf leans on the much larger Steffan trial below for its stamp. The abstract reports significance tests for the reductions rather than the percentage reductions themselves, so no group percentages are carded.

Olivry T, Rivierre C, Jackson HA, Murphy KM, Davidson G, Sousa CA. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial. Vet Dermatol. 2002;13(2):77-87. PMID: 11972891. Registry ID: none in the record. MeSH: Administration, Oral · Animals · California · Cyclosporine · Dermatitis, Atopic · Dermatologic Agents · Dog Diseases · Dogs · Double-Blind Method · Female · Male · North Carolina · Prednisolone · Prospective Studies · Pruritus · Severity of Illness Index · Treatment Outcome · Virginia

Steffan 2003: ciclosporin vs methylprednisolone — lesion scores fell 52% vs 45% and pruritus 36% vs 33%, not significantly different

Multicentre, parallel, blinded, randomized controlled trial (record's own abstract wording; indexed Randomized Controlled Trial, with MeSH Double-Blind Method)

Who: Dogs: dogs with atopic dermatitis in a multicentre trial — 117 dogs treated with cyclosporine (CsA group) and 59 with methylprednisolone (MP group); mean induction doses were 5 mg/kg CsA and 0.75 mg/kg MP, both tapered over time according to clinical response, over a 4-month treatment period (longer than the 6–8-week window in this shelf's question; the trial's end-of-study figures are carded as reported).

Result: At the end of the study, the mean estimated percentage reduction from baseline (confidence interval) of lesion scores was 52% (44-59) in the CsA group and 45% (35-56) in the MP group, and the reduction in pruritus score was 36% (27-43) and 33% (23-43) respectively; these percentages were not significantly different between groups. A significantly better overall assessment of efficacy was obtained in the CsA-treated dogs (76 vs 63% responses rated excellent or good in the CsA compared with MP group). CsA-treated dogs had a higher frequency of gastrointestinal disorders, mainly vomiting, but MP dogs tended to be more susceptible to infections; there was no remarkable change over baseline in haematological and biochemical parameters in either group.

Watch out: Doses of both drugs were tapered by response over 4 months, so this is a comparison of two tapered treatment strategies, not of fixed doses at 6–8 weeks — the 6-week equivalence point rests on Olivry 2002 above. Unequal group sizes (117 vs 59) reflect the trial's allocation, and the 'overall assessment' advantage for ciclosporin is a global clinician judgement, softer than the lesion and pruritus scores, which did not differ.

Steffan J, Alexander D, Brovedani F, Fisch RD. Comparison of cyclosporine A with methylprednisolone for treatment of canine atopic dermatitis: a parallel, blinded, randomized controlled trial. Vet Dermatol. 2003;14(1):11-22. PMID: 12603681. Registry ID: none in the record. MeSH: Administration, Oral · Animals · Anti-Inflammatory Agents · Cyclosporine · Dermatitis, Atopic · Dermatologic Agents · Dog Diseases · Dogs · Double-Blind Method · Drug Administration Schedule · Female · Male · Methylprednisolone · Treatment Outcome

Steffan 2004: after stopping, 62% of ciclosporin dogs relapsed (mean 40.7 days) vs 87% of methylprednisolone dogs (mean 27.9 days)

Randomised controlled trial follow-up after treatment cessation (indexed Randomized Controlled Trial, with MeSH Double-Blind Method and Follow-Up Studies)

Who: Dogs: 78 dogs with atopic dermatitis that had been treated for four months with either cyclosporin A or methylprednisolone (the Steffan programme's trial cohort), followed for the two months after treatment ceased, in a multicentre setting; clinical condition was evaluated at relapse or at two months if the dog had not relapsed.

Result: During the two months after treatment ceased, 87 per cent of the dogs treated with methylprednisolone relapsed after a mean period of 27.9 days, whereas only 62 per cent of the dogs treated with cyclosporin A relapsed after a mean period of 40.7 days (P < 0.001 as printed in the record). Skin lesions and pruritus increased significantly more markedly after cessation in the methylprednisolone dogs than in the cyclosporin A dogs. In dogs that did not relapse, the lesion score was improved by 77 per cent two months after treatment stopped (both groups); in dogs that did relapse, lesion scores had improved by 45 per cent (cyclosporin A) and 35 per cent (methylprednisolone). Pruritus remained well controlled in dogs that did not relapse but increased to baseline levels or close to baseline in dogs that relapsed.

Watch out: This follow-up answers a different question — durability after stopping — from the 6–8-week control question, and its 78 dogs are a subset of the treated population, so it supports, but does not carry, the equivalence claim. It does show the two drugs are not interchangeable in every respect: control persists longer after ciclosporin is withdrawn.

Steffan J, Horn J, Gruet P, Strehlau G, Fondati A, Ferrer L, Noli C. Remission of the clinical signs of atopic dermatitis in dogs after cessation of treatment with cyclosporin A or methylprednisolone. Vet Rec. 2004;154(22):681-4. PMID: 15200072. Registry ID: none in the record. MeSH: Animals · Anti-Inflammatory Agents · Cyclosporine · Dermatitis, Atopic · Dermatologic Agents · Dog Diseases · Dogs · Double-Blind Method · Follow-Up Studies · Methylprednisolone · Pruritus · Recurrence · Risk Factors · Severity of Illness Index · Skin · Treatment Outcome

Synthesis: two blinded randomised trials agree — ciclosporin matches a glucocorticoid on lesions and itch, and outlasts it after stopping

Synthesis

Who: Synthesis of the cards above: Olivry 2002 (blinded randomised trial, 30 dogs, ciclosporin vs prednisolone for 6 weeks); Steffan 2003 (multicentre blinded randomised trial, 117 ciclosporin vs 59 methylprednisolone dogs, tapered over 4 months); Steffan 2004 (post-cessation follow-up of 78 dogs from the same programme).

Result: At 6 weeks (Olivry) and over a tapered 4-month course (Steffan), lesion and pruritus reductions on ciclosporin were statistically indistinguishable from those on prednisolone or methylprednisolone, with ciclosporin ahead only on a global efficacy assessment (76% vs 63% excellent or good) and on time to relapse after withdrawal (mean 40.7 vs 27.9 days; 62% vs 87% relapsed). The honest claim is comparable control, not proven exact equivalence — neither trial pre-set an equivalence margin — and the adverse-effect trade differs: more gastrointestinal upset, mainly vomiting, on ciclosporin; more infection susceptibility on methylprednisolone. That consistent, blinded, two-trial picture is what carries LIKELY.

Watch out: Anchor note: the draft's 'Steffan et al. 2006' citation is a review, not a trial, and is not carded; the genuine trials are Olivry 2002 (prednisolone, 6 weeks) and Steffan 2003 (methylprednisolone, 4 months). Ciclosporin's slower onset in practice and its cost are not measured in these records and are not part of this stamp.

Synthesis of Olivry T et al. PMID: 11972891; Steffan J et al. PMID: 12603681; Steffan J et al. PMID: 15200072. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.